Literature DB >> 3244603

Release of lonapalene from two-phase emulsion-type ointment systems.

J T Ong1, E Manoukian.   

Abstract

The in vitro release of lonapalene, a novel nonsteroidal antipsoriatic agent, was studied from two-phase emulsion-type ointment systems into a perfect sink of propylene carbonate at 32 degrees C. Lonapalene was completely solubilized in the ointments consisting of an internal phase of propylene carbonate (PC)-propylene glycol (PG) mixture dispersed within an external phase of a petrolatum base. The PC:PG ratio was varied to investigate separately the effects of (1) the initial concentration of lonapalene, (2) its saturation level, and (3) the volume fraction of the internal phase. The release profile consisted of an initial release rate which was higher than the ensuing diffusion-controlled release rate. The initial rate was attributed to the release of lonapalene from the surface globules of internal phase directly into the sink. Both rates increased with increasing lonapalene initial concentration in the ointment. For ointment systems in which the saturation level of lonapalene was kept constant, neither release rate was affected by the increasing volume fraction of the internal phase up to 12%. Further increase in this volume fraction to 25% afforded a significantly higher initial rate, while the diffusion-controlled rate was unchanged. However, an increase in the volume fraction of the internal phase with a concomitant decrease in the saturation level of lonapalene in the ointment resulted in a decrease in the initial rates and, to a lesser degree, the diffusion-controlled release rates. The diffusion coefficient in the external phase, calculated from the effective diffusion coefficient, was (2.68 +/- 0.24) X 10(-9) cm2/sec.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3244603     DOI: 10.1023/a:1015803226249

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Analysis of data on the medicament release from ointments.

Authors:  W I HIGUCHI
Journal:  J Pharm Sci       Date:  1962-08       Impact factor: 3.534

2.  Development and evaluation of ointment and cream vehicles for a new topical steroid, fluclorolone acetonide.

Authors:  T Malone; J K Haleblian; B J Poulsen; K H Burdick
Journal:  Br J Dermatol       Date:  1974-02       Impact factor: 9.302

3.  Effect of topical vehicle composition on the in vitro release of fluocinolone acetonide and its acetate ester.

Authors:  B J Poulsen; E Young; V Coquilla; M Katz
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

4.  A dimethoxynaphthalene derivative (RS-43179 gel) compared with 0.025% fluocinolone acetonide gel in the treatment of psoriasis.

Authors:  A Lassus; S Forsstrom
Journal:  Br J Dermatol       Date:  1985-07       Impact factor: 9.302

5.  Vehicle design for a new topical steroid, fluocinonide.

Authors:  J Ostrenga; J Haleblian; B Poulsen; B Ferrell; N Mueller; S Shastri
Journal:  J Invest Dermatol       Date:  1971-05       Impact factor: 8.551

6.  In vitro and in vivo studies on lidocaine formulated in an o/w cream and in a polyethylene glycol ointment.

Authors:  F Broberg; A Brodin; B Akerman; S G Frank
Journal:  Acta Pharm Suec       Date:  1982

7.  Topical nonsteroidal antipsoriatic agents. 1. 1,2,3,4-Tetraoxygenated naphthalene derivatives.

Authors:  G H Jones; M C Venuti; J M Young; D V Murthy; B E Loe; R A Simpson; A H Berks; D A Spires; P J Maloney; M Kruseman
Journal:  J Med Chem       Date:  1986-08       Impact factor: 7.446

8.  Release of corticoids from oleaginous ointment bases containing drug in suspension.

Authors:  Z T Chowhan; R Pritchard
Journal:  J Pharm Sci       Date:  1975-05       Impact factor: 3.534

  8 in total
  1 in total

Review 1.  Perspectives on Physicochemical and In Vitro Profiling of Ophthalmic Ointments.

Authors:  Quanying Bao; Diane J Burgess
Journal:  Pharm Res       Date:  2018-10-15       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.